Sanofi

Press Release: Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old

over 1 year ago

Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis...

Press Release: Tolebrutinib demonstrated a 31% delay in time to onset of confirmed disability progression in non-relapsing secondary progressive multiple sclerosis phase 3 study

over 1 year ago

Tolebrutinib demonstrated a 31% delay in time to onset of confirmed disability...

Press Release: Sanofi, RadioMedix, and Orano Med announce licensing agreement on next-generation radioligand medicine for rare cancers

over 1 year ago

Sanofi, RadioMedix, and Orano Med announce licensing agreement on next-generation radioligand medicine...

Press Release: Dupixent phase 3 study confirms significant improvements in itch and hives for patients with CSU

over 1 year ago

Press Release: Dupixent is the first and only biologic to achieve significant improvements in disease remission and symptoms in bullous pemphigoid positive pivotal study

over 1 year ago

Media Update: ERS: Dupixent data reinforce clinically meaningful benefit from pooled analysis of two COPD phase 3 studies

over 1 year ago

ERS: Dupixent data reinforce clinically meaningful benefit from pooled analysis of two...

Press Release: Tolebrutinib meets primary endpoint in HERCULES phase 3 study, the first and only to show reduction in disability accumulation in non-relapsing secondary progressive multiple sclerosis

over 1 year ago

Media Update: ERS: New data highlight Sanofi’s scientific innovation and leadership in immune-mediated respiratory diseases

over 1 year ago

ERS: New data highlight Sanofi’s scientific innovation and leadership in immune-mediated respiratory...

Press Release: Sarclisa induction treatment demonstrated significantly improved progression-free survival in patients with newly diagnosed multiple myeloma eligible for transplant

over 1 year ago

Sarclisa induction treatment demonstrated significantly improved progression-free survival in patients with newly...

Press Release: Online availability of Sanofi’s half-year financial report for 2024

over 1 year ago

Online availability of Sanofi’s half-year financial report for 2024

Press Release: Sanofi Q2 - strong performance with 10% sales growth; 2024 guidance upgraded

over 1 year ago

Sanofi Q2: strong performance with 10% sales growth; 2024 guidance upgraded

Press Release: NEJM publishes ALTUVIIIO XTEND-Kids phase 3 data supporting its potential to transform the treatment landscape for children with severe hemophilia A

over 1 year ago